PRPH icon

ProPhase Labs

0.4185 USD
+0.0148
3.67%
At close Jul 3, 4:00 PM EDT
After hours
0.4100
-0.0085
2.03%
1 day
3.67%
5 days
20.61%
1 month
9.90%
3 months
20.95%
6 months
-49.68%
Year to date
-52.44%
1 year
-88.47%
5 years
-70.11%
10 years
-70.32%
 

About: ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.

Employees: 96

0
Funds holding %
of 7,310 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

140% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 5

23% more funds holding

Funds holding: 30 [Q4 2024] → 37 (+7) [Q1 2025]

6.59% more ownership

Funds ownership: 10.13% [Q4 2024] → 16.72% (+6.59%) [Q1 2025]

5% more capital invested

Capital invested by funds: $1.91M [Q4 2024] → $2.02M (+$103K) [Q1 2025]

0% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 8

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Research analyst outlook

We haven’t received any recent analyst ratings for PRPH.

Financial journalist opinion

Based on 3 articles about PRPH published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following the expiration of the initial 180 calendar days period to regain compliance on June 24, 2025. NASDAQ stated that it based its determination to grant the extension based on the Company meeting all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement.
ProPhase Labs, Inc. Receives Additional 180 Day Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
Neutral
GlobeNewsWire
2 weeks ago
ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer
BE-Smart represents a significant advance in diagnosis and management of Esophageal disease that affects an estimated 60 million people in the United States
ProPhase Labs Announces Successful Study Demonstrating Performance of BE-Smart™ Test in Detecting Esophageal Cancer
Neutral
GlobeNewsWire
1 month ago
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
UNIONDALE, NY, June 06, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced the formation of its Clinical Science Advisory Board to support the clinical adoption and commercialization of its breakthrough BE-SmartTM molecular test for esophageal disease. The advisory board will provide expert strategic guidance as ProPhase leads the regulatory and commercialization pathway for BE-Smart, with the goal of establishing a new clinical and economic standard in the early detection and management of esophageal cancer risk.
ProPhase Labs Announces Formation of Clinical Science Advisory Board to Accelerate Commercialization of BE-SmartTM Esophageal Disease Diagnostic Platform
Neutral
Seeking Alpha
1 month ago
ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q1 2025 Earnings Conference Call May 20, 2025 10:00 AM ET Company Participants Noella Alexander-Young - Virtual Event Moderator, Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Hello, and good morning everyone. Welcome to today's presentation.
ProPhase Labs, Inc. (PRPH) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025
Highlights Multiple Significant Potential Liquidity Events Anticipated Within the Next Few Months Completes Significant Reductions in Overhead and Expenses BE-Smart Esophageal Cancer Test Study has been Submitted in the Journal of Clinical Gastrointestinal Hepatology Company to hold a virtual conference call Tuesday, May 20, 2025, at 10:00 AM ET GARDEN CITY, NY, May 20, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today reported its financial and operational results for Q1 ended March 31, 2025, and outlined significant strategic corporate developments. Ted Karkus, CEO of ProPhase Labs, will present to shareholders today, May 20, 2025, at 10:00 a.m.
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2025
Neutral
GlobeNewsWire
1 month ago
ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025
GARDEN CITY, NY, May 13, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, announced today that they will be presenting first quarter 2025 financial results on a virtual conference call hosted by Renmark Financial on May 20, 2025, at 10:00 am EDT. Ted Karkus, CEO, looks forward to providing shareholders with an update on several positive activities, including the initiative to sell the Company's wholly owned subsidiary, Nebula Genomics, and the Crown Medical Collections initiative to collect tens of millions of dollars in accounts receivable.
ProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025
Neutral
Seeking Alpha
3 months ago
ProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q4 2024 Earnings Conference Call March 31, 2025 11:00 AM ET Company Participants Noella Alexander-Young - Virtual Event Moderator, Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Noella Alexander-Young Hello and good morning, everyone. Welcome to today's presentation.
ProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
Company to Accelerate BE-Smart Commercialization as a Cash-Pay Diagnostic Significantly reduces overhead, improves margins heading into Q2 2025 Company to hold a conference call Monday, March 31, 2025, at 11:00 AM EST GARDEN CITY, NY, March 31, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today reported its financial and operational results for the full-year ended December 31, 2024 and outlined strategic corporate developments aimed at realigning the Company for sustained long-term growth, profitability, and strategic focus. Ted Karkus, CEO of ProPhase Labs, will present to shareholders today, March 31, 2025, at 11:00 a.m.
ProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024
Neutral
GlobeNewsWire
3 months ago
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
GARDEN CITY, NY, March 27, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and consumer products company, today announced that they will be presenting full year 2024 financial results, and a review of current Company strategy, on a virtual conference call hosted by Renmark Financial on March 31, 2025 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
ProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025
Neutral
GlobeNewsWire
3 months ago
ProPhase Labs to Present at the Investor Summit Virtual on March 11
GARDEN CITY, NY, March 07, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced that Ted Karkus, CEO, will be presenting at this year's Investor Summit Virtual on March 11th.
ProPhase Labs to Present at the Investor Summit Virtual on March 11
Charts implemented using Lightweight Charts™